These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 30582813)
1. Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. Perry MWD; Abdulai R; Mogemark M; Petersen J; Thomas MJ; Valastro B; Westin Eriksson A J Med Chem; 2019 May; 62(10):4783-4814. PubMed ID: 30582813 [TBL] [Abstract][Full Text] [Related]
2. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. Garces AE; Stocks MJ J Med Chem; 2019 May; 62(10):4815-4850. PubMed ID: 30582807 [TBL] [Abstract][Full Text] [Related]
3. Recent discovery of phosphoinositide 3-kinase γ inhibitors for the treatment of immune diseases and cancers. Qiu X; Tian Y; Liang Z; Sun Y; Li Z; Bian J Future Med Chem; 2019 Aug; 11(16):2151-2169. PubMed ID: 31538525 [TBL] [Abstract][Full Text] [Related]
4. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors. Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293 [TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells. Zhang Z; Liu J; Wang Y; Tan X; Zhao W; Xing X; Qiu Y; Wang R; Jin M; Fan G; Zhang P; Zhong Y; Kong D FASEB J; 2018 Nov; 32(11):5967-5975. PubMed ID: 29792732 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Pyrazolo[1,5- Wang C; Zou F; Qi Z; Liu Q; Shen L; Yuan X; Deng M; Wang A; Wang B; Wang L; Liang X; Liu Q; Liu J J Med Chem; 2024 Sep; 67(17):15199-15219. PubMed ID: 39163191 [TBL] [Abstract][Full Text] [Related]
7. Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors. Zhu J; Li K; Yu L; Chen Y; Cai Y; Jin J; Hou T Med Res Rev; 2021 May; 41(3):1599-1621. PubMed ID: 33300614 [TBL] [Abstract][Full Text] [Related]
8. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment. Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033 [TBL] [Abstract][Full Text] [Related]
9. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors. Ma CC; Zhang CM; Tang LQ; Liu ZP Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991 [TBL] [Abstract][Full Text] [Related]
10. Development of PI3Kγ selective inhibitors: the strategies and application. Gu DY; Zhang MM; Li J; Zhou YB; Sheng R Acta Pharmacol Sin; 2024 Feb; 45(2):238-247. PubMed ID: 37803138 [TBL] [Abstract][Full Text] [Related]
12. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration. Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062 [TBL] [Abstract][Full Text] [Related]
13. A class of highly selective inhibitors bind to an active state of PI3Kγ. Gangadhara G; Dahl G; Bohnacker T; Rae R; Gunnarsson J; Blaho S; Öster L; Lindmark H; Karabelas K; Pemberton N; Tyrchan C; Mogemark M; Wymann MP; Williams RL; Perry MWD; Papavoine T; Petersen J Nat Chem Biol; 2019 Apr; 15(4):348-357. PubMed ID: 30718815 [TBL] [Abstract][Full Text] [Related]
14. PI3Kγδ inhibition suppresses key disease features in a rat model of asthma. Pinkerton JW; Preite S; Piras A; Zervas D; Markou T; Freeman MS; Hofving T; Ivarsson E; Bonvini SJ; Brailsford W; Yrlid L; Belvisi MG; Birrell MA Respir Res; 2024 Apr; 25(1):175. PubMed ID: 38654248 [TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma. Ameriks MK; Venable JD Curr Top Med Chem; 2009; 9(8):738-53. PubMed ID: 19689378 [TBL] [Abstract][Full Text] [Related]
16. Designing Small Molecule PI3Kγ Inhibitors: A Review of Structure-Based Methods and Computational Approaches. Yin X; Wang J; Ge M; Feng X; Zhang G J Med Chem; 2024 Jul; 67(13):10530-10547. PubMed ID: 38988222 [TBL] [Abstract][Full Text] [Related]
17. PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases. Cushing TD; Metz DP; Whittington DA; McGee LR J Med Chem; 2012 Oct; 55(20):8559-81. PubMed ID: 22924688 [No Abstract] [Full Text] [Related]
18. Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation. Stark AK; Davenport ECM; Patton DT; Scudamore CL; Vanhaesebroeck B; Veldhoen M; Garden OA; Okkenhaug K J Immunol; 2020 Jul; 205(1):78-89. PubMed ID: 32414808 [TBL] [Abstract][Full Text] [Related]
19. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential. Ghigo A; Hirsch E Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988 [TBL] [Abstract][Full Text] [Related]
20. Anti-inflammation effects of naloxone involve phosphoinositide 3-kinase delta and gamma. Wang TY; Su NY; Shih PC; Tsai PS; Huang CJ J Surg Res; 2014 Dec; 192(2):599-606. PubMed ID: 25016442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]